DVAX Dynavax Technologies Corp

Price (delayed)

$12.41

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$1.72B

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of ...

Highlights
DVAX's gross margin is up by 23% YoY and by 17% QoQ
Dynavax Technologies's equity has increased by 7% YoY and by 2.8% from the previous quarter
DVAX's quick ratio has soared by 146% YoY but it is down by 11% QoQ
The net income has dropped by 110% since the previous quarter and by 102% year-on-year
DVAX's EPS has plunged by 110% from the previous quarter and by 102% YoY

Key stats

What are the main financial stats of DVAX
Market
Shares outstanding
130.61M
Market cap
$1.62B
Enterprise value
$1.72B
Valuations
Price to book (P/B)
2.58
Price to sales (P/S)
6.88
EV/EBIT
720.95
EV/EBITDA
178.26
EV/Sales
7.42
Earnings
Revenue
$232.28M
EBIT
$2.39M
EBITDA
$9.67M
Free cash flow
$97.46M
Per share
EPS
-$0.05
Free cash flow per share
$0.76
Book value per share
$4.81
Revenue per share
$1.8
TBVPS
$7.73
Balance sheet
Total assets
$997.1M
Total liabilities
$375.02M
Debt
$252.42M
Equity
$622.07M
Working capital
$796.93M
Liquidity
Debt to equity
0.41
Current ratio
13.81
Quick ratio
12.65
Net debt/EBITDA
10.57
Margins
EBITDA margin
4.2%
Gross margin
78.4%
Net margin
-2.8%
Operating margin
-15.9%
Efficiency
Return on assets
-0.7%
Return on equity
-1.1%
Return on invested capital
0.2%
Return on capital employed
0.3%
Return on sales
1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DVAX stock price

How has the Dynavax Technologies stock price performed over time
Intraday
0%
1 week
2.06%
1 month
-4.17%
1 year
27.15%
YTD
-11.23%
QTD
-11.23%

Financial performance

How have Dynavax Technologies's revenue and profit performed over time
Revenue
$232.28M
Gross profit
$182.12M
Operating income
-$37.03M
Net income
-$6.39M
Gross margin
78.4%
Net margin
-2.8%
The company's operating margin has shrunk by 141% YoY
Dynavax Technologies's net margin has plunged by 117% from the previous quarter and by 107% YoY
DVAX's operating income has dropped by 113% year-on-year
The net income has dropped by 110% since the previous quarter and by 102% year-on-year

Growth

What is Dynavax Technologies's growth rate over time

Valuation

What is Dynavax Technologies stock price valuation
P/E
N/A
P/B
2.58
P/S
6.88
EV/EBIT
720.95
EV/EBITDA
178.26
EV/Sales
7.42
DVAX's EPS has plunged by 110% from the previous quarter and by 102% YoY
DVAX's P/B is 79% below its 5-year quarterly average of 12.2 and 8% below its last 4 quarters average of 2.8
Dynavax Technologies's equity has increased by 7% YoY and by 2.8% from the previous quarter
DVAX's revenue has dropped by 68% year-on-year and by 36% since the previous quarter
The P/S is 50% more than the last 4 quarters average of 4.6 but 23% less than the 5-year quarterly average of 8.9

Efficiency

How efficient is Dynavax Technologies business performance
Dynavax Technologies's ROA has plunged by 111% from the previous quarter and by 102% YoY
The ROE has plunged by 110% from the previous quarter and by 102% YoY
Dynavax Technologies's return on invested capital has shrunk by 100% YoY and by 97% QoQ
DVAX's ROS has plunged by 98% YoY and by 95% from the previous quarter

Dividends

What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DVAX.

Financial health

How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 166% higher than its total liabilities
DVAX's quick ratio has soared by 146% YoY but it is down by 11% QoQ
Dynavax Technologies's current ratio has surged by 126% YoY but it has decreased by 10% QoQ
Dynavax Technologies's debt is 59% less than its equity
Dynavax Technologies's equity has increased by 7% YoY and by 2.8% from the previous quarter
The debt to equity has contracted by 7% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.